Arvin Adler, DO
Radiation Oncology · Passaic, NJNPI 1265430433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations.
Across 78 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$285
- Novartis$218
- AstraZeneca$157
- Bayer$106
- Johnson & Johnson$71
- Regeneron Healthcare Solutions, Inc.$62
- plus $485 from 20 others
What the payments were for
- Food & beverage$1,383100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 17 | $285 |
| Novartis | 11 | $218 |
| AstraZeneca | 10 | $157 |
| Bayer | 5 | $106 |
| Johnson & Johnson | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $62 |
| Telix Pharmaceuticals | 3 | $48 |
| Lilly USA, LLC | 2 | $39 |
| Mirati Therapeutics, Inc. | 2 | $38 |
| Taiho Oncology, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $30 |
| Acrotech Biopharma Inc. | 1 | $26 |
| Organogenesis Inc. | 1 | $25 |
| Blue Earth Diagnostics | 2 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $20 |
| Amgen | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $13 |
How this compares
$1,383 in reported general payments places this provider in the 70th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Passaic
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Timothy ChenPennington$43K
- Brett LewisHackensack$23K
- Sang SimLong Branch$16K
- Thomas KoleMiddletown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.